Cingulate_Logo_400x400_twitter.jpg
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
February 13, 2024 06:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Closing of $7.5 Million Public Offering
February 06, 2024 16:15 ET | Cingulate Inc.
KANSAS CITY, Kan., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Announces Pricing of $7.5 Million Public Offering
February 02, 2024 09:15 ET | Cingulate Inc.
KANSAS CITY, Kan., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (“Cingulate,” the “Company,” “we,” “our” or “us”), a biopharmaceutical company utilizing its proprietary Precision...
Cingulate_Logo_400x400_twitter.jpg
Longtime Cingulate Controller Jennifer Callahan Promoted to CFO
January 29, 2024 08:00 ET | Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Cingulate_Logo_400x400_twitter.jpg
Werth Family Investment Associates Converts Remaining $3.3M of Debt and Accrued Interest into Cingulate Equity at Premium to Market
January 29, 2024 06:45 ET | Cingulate Inc.
KANSAS CITY, Kan., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) (Cingulate), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery...
Research Nester Logo.jpg
Behavioral Health Market revenue to surpass USD 67 Billion by 2033, says Research Nester
January 22, 2024 05:00 ET | Research Nester
New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The global behavioral health market size is projected to expand at ~5% CAGR between 2023 and 2033. The market is expected to garner a revenue of USD 67...
NeuroSigma.png
NeuroSigma Announces FDA Clearance of its Second-Generation Monarch eTNS System for Treating Pediatric ADHD
January 18, 2024 00:21 ET | NeuroSigma, Inc.
LOS ANGELES, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NeuroSigma today announced that the U.S. Food and Drug Administration (FDA) cleared use of NeuroSigma’s second-generation Monarch eTNS System for...
dd-logo.png
UK’s Psychiatrist-Led Diverse Diagnostics Offers Private ADHD Assessment with Free Consultations
January 12, 2024 09:00 ET | Diverse Diagnostics
Glasgow, United Kingdom, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Diverse Diagnostics, a leading psychiatric clinic based in the United Kingdom, announces the launch of its specialised service offering...
Done. Reaches Milest
Done. Reaches Milestone in Opening 30 Physical Clinic Locations
December 04, 2023 09:00 ET | Done.
San Francisco, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Done., a patient-first startup established by a team of experts dedicated to supporting the millions of adults facing the ADHD and mental health...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Inc. Reports Third Quarter 2023 Financial Results and Provides Clinical and Business Update
November 13, 2023 16:15 ET | Cingulate Inc.
Phase 3 Adult Efficacy and Safety Trial Data Presented at Psych Congress Cingulate Closed a $4M Public Offering $5.8M of Debt Converted into CING Equity KANSAS CITY, Kan., Nov. 13, 2023 (GLOBE...